Who are Nasal Glucagon (NG)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Glucagon 12.5ng/kg/min, Low-Dose Glucagon, Glucagon IM, CagriSema, Glucagon Hydrochloride Solution, Intramuscular Glucagon.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nasal-glucagon-ng.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nasal Glucagon (NG) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nasal Glucagon (NG) (Nasal Glucagon (NG)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glucagon receptor agonist. Area: Endocrinology.

phase 3 Glucagon receptor agonist Glucagon receptor (GCGR) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Nasal Glucagon (NG) (Nasal Glucagon (NG)) — Eli Lilly and Company. Nasal glucagon activates glucagon receptors to rapidly increase blood glucose levels in hypoglycemic emergencies.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Nasal Glucagon (NG) TARGET	Nasal Glucagon (NG)	Eli Lilly and Company	phase 3	Glucagon receptor agonist	Glucagon receptor (GCGR)
Glucagon 12.5ng/kg/min	Glucagon 12.5ng/kg/min	Cambridge University Hospitals NHS Foundation Trust	marketed	Glucagon receptor agonist	Glucagon receptor (GCGR)
Low-Dose Glucagon	Low-Dose Glucagon	Steno Diabetes Center Copenhagen	marketed	Glucagon receptor agonist	Glucagon receptor (GCGR)
Glucagon IM	Glucagon IM	Eli Lilly and Company	phase 3	Glucagon receptor agonist	Glucagon receptor (GCGR)
CagriSema	CagriSema	Novo Nordisk A/S	phase 3	Dual GLP-1/glucagon receptor agonist	GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR)
Glucagon Hydrochloride Solution	Glucagon Hydrochloride Solution	Eli Lilly and Company	phase 3	Glucagon receptor agonist	Glucagon receptor (GCGR)
Intramuscular Glucagon	Intramuscular Glucagon	Eli Lilly and Company	phase 3	Glucagon receptor agonist	GCGR (glucagon receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glucagon receptor agonist class)

Eli Lilly and Company · 5 drugs in this class
Adocia · 1 drug in this class
Cambridge University Hospitals NHS Foundation Trust · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Steno Diabetes Center Copenhagen · 1 drug in this class
SynAct Pharma Aps · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nasal Glucagon (NG) — Competitive Intelligence Brief. https://druglandscape.com/ci/nasal-glucagon-ng. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab